Preservative-free bimatoprost 0.03%/timolol 0.5% fixed combination in patients with glaucoma in clinical practice

Stefan Pfennigsdorf,1 Peter Eschstruth,2 Stefan Häsemeyer,3 Cord Feuerhake,4 Gerrett Brief,5 Ioana Grobeiu,6 Andrew Shirlaw6 1Polch Ophthalmology Practice, Polch, 2Ophthalmology Practice, Kiel, 3Ophthalmology Practice, Wiesloch, 4Ophthalmology Practice, Lehrte, 5Ophthalmology Practice, Dor...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Pfennigsdorf S, Eschstruth P, Häsemeyer S, Feuerhake C, Brief G, Grobeiu I, Shirlaw A
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	bimatoprost 0.03%/timolol 0.5% intraocular pressure prostaglandin preservative-free glaucoma fixed-combination Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/ecf91b7b927544dbab46409aca22c4e2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ecf91b7b927544dbab46409aca22c4e2
record_format	dspace
spelling	oai:doaj.org-article:ecf91b7b927544dbab46409aca22c4e22021-12-02T06:58:43ZPreservative-free bimatoprost 0.03%/timolol 0.5% fixed combination in patients with glaucoma in clinical practice1177-5483https://doaj.org/article/ecf91b7b927544dbab46409aca22c4e22016-09-01T00:00:00Zhttps://www.dovepress.com/preservative-free-bimatoprost-003timolol-05-fixed-combination-in-patie-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Stefan Pfennigsdorf,1 Peter Eschstruth,2 Stefan Häsemeyer,3 Cord Feuerhake,4 Gerrett Brief,5 Ioana Grobeiu,6 Andrew Shirlaw6 1Polch Ophthalmology Practice, Polch, 2Ophthalmology Practice, Kiel, 3Ophthalmology Practice, Wiesloch, 4Ophthalmology Practice, Lehrte, 5Ophthalmology Practice, Dortmund, Germany; 6Allergan Holdings Ltd., Marlow, UK Purpose: The aim of this study was to evaluate the efficacy and tolerability of, and compliance to, preservative-free (PF), fixed-combination (FC) bimatoprost 0.03%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension in a clinical practice setting.Patients and methods: This open-label study observed patients switched to PF FC bimatoprost 0.03%/timolol 0.5% due to insufficient intraocular pressure (IOP) control on previous therapies. IOP was measured at baseline and at ~12 weeks. Tolerability and continuation of therapy were also assessed.Results: A total of 1,553 patients were included in the study, and the per-protocol population comprised 1,391 patients. There were some minor deviations from protocol: some patients with no prior therapy and some who switched for reasons other than insufficient IOP control were included in the analysis. The mean IOP was reduced by 27.4%, from 22.2 mmHg to 16.1 mmHg. In subgroup analyses, the mean IOP was significantly reduced from baseline, irrespective of whether previous treatment was monotherapy or combination therapy, and preserved or PF therapy. Physicians mostly (88.1%) reported the IOP-lowering efficacy of PF FC bimatoprost 0.03%/timolol 0.5% to be as expected or better than expected. Switching to PF FC bimatoprost 0.03%/timolol 0.5% resulted in reductions from baseline in the number of patients reporting ocular symptoms. Adverse events were reported by 6.2% of patients, the most common being eye irritation (1.6%) and eye pruritus (1.0%). Physicians reported treatment compliance as better or unchanged compared with prior treatment in almost all patients (93.9%). Most patients were expected to continue PF FC bimatoprost 0.03%/timolol 0.5% after the end of the study.Conclusion: Switching to PF FC bimatoprost 0.03%/timolol 0.5% was associated with significant IOP reductions from baseline over 12 weeks. Adverse events were uncommon, and compliance was high compared with previous therapy. PF FC bimatoprost 0.03%/timolol 0.5% may be a suitable treatment for patients with inadequately controlled IOP or who are sensitive to preservatives. Keywords: bimatoprost 0.03%/timolol 0.5%, intraocular pressure, prostaglandin, preservative free, glaucoma, fixed combinationPfennigsdorf SEschstruth PHäsemeyer SFeuerhake CBrief GGrobeiu IShirlaw ADove Medical Pressarticlebimatoprost 0.03%/timolol 0.5%intraocular pressureprostaglandinpreservative-freeglaucomafixed-combinationOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 10, Pp 1837-1846 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	bimatoprost 0.03%/timolol 0.5% intraocular pressure prostaglandin preservative-free glaucoma fixed-combination Ophthalmology RE1-994
spellingShingle	bimatoprost 0.03%/timolol 0.5% intraocular pressure prostaglandin preservative-free glaucoma fixed-combination Ophthalmology RE1-994 Pfennigsdorf S Eschstruth P Häsemeyer S Feuerhake C Brief G Grobeiu I Shirlaw A Preservative-free bimatoprost 0.03%/timolol 0.5% fixed combination in patients with glaucoma in clinical practice
description	Stefan Pfennigsdorf,1 Peter Eschstruth,2 Stefan Häsemeyer,3 Cord Feuerhake,4 Gerrett Brief,5 Ioana Grobeiu,6 Andrew Shirlaw6 1Polch Ophthalmology Practice, Polch, 2Ophthalmology Practice, Kiel, 3Ophthalmology Practice, Wiesloch, 4Ophthalmology Practice, Lehrte, 5Ophthalmology Practice, Dortmund, Germany; 6Allergan Holdings Ltd., Marlow, UK Purpose: The aim of this study was to evaluate the efficacy and tolerability of, and compliance to, preservative-free (PF), fixed-combination (FC) bimatoprost 0.03%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension in a clinical practice setting.Patients and methods: This open-label study observed patients switched to PF FC bimatoprost 0.03%/timolol 0.5% due to insufficient intraocular pressure (IOP) control on previous therapies. IOP was measured at baseline and at ~12 weeks. Tolerability and continuation of therapy were also assessed.Results: A total of 1,553 patients were included in the study, and the per-protocol population comprised 1,391 patients. There were some minor deviations from protocol: some patients with no prior therapy and some who switched for reasons other than insufficient IOP control were included in the analysis. The mean IOP was reduced by 27.4%, from 22.2 mmHg to 16.1 mmHg. In subgroup analyses, the mean IOP was significantly reduced from baseline, irrespective of whether previous treatment was monotherapy or combination therapy, and preserved or PF therapy. Physicians mostly (88.1%) reported the IOP-lowering efficacy of PF FC bimatoprost 0.03%/timolol 0.5% to be as expected or better than expected. Switching to PF FC bimatoprost 0.03%/timolol 0.5% resulted in reductions from baseline in the number of patients reporting ocular symptoms. Adverse events were reported by 6.2% of patients, the most common being eye irritation (1.6%) and eye pruritus (1.0%). Physicians reported treatment compliance as better or unchanged compared with prior treatment in almost all patients (93.9%). Most patients were expected to continue PF FC bimatoprost 0.03%/timolol 0.5% after the end of the study.Conclusion: Switching to PF FC bimatoprost 0.03%/timolol 0.5% was associated with significant IOP reductions from baseline over 12 weeks. Adverse events were uncommon, and compliance was high compared with previous therapy. PF FC bimatoprost 0.03%/timolol 0.5% may be a suitable treatment for patients with inadequately controlled IOP or who are sensitive to preservatives. Keywords: bimatoprost 0.03%/timolol 0.5%, intraocular pressure, prostaglandin, preservative free, glaucoma, fixed combination
format	article
author	Pfennigsdorf S Eschstruth P Häsemeyer S Feuerhake C Brief G Grobeiu I Shirlaw A
author_facet	Pfennigsdorf S Eschstruth P Häsemeyer S Feuerhake C Brief G Grobeiu I Shirlaw A
author_sort	Pfennigsdorf S
title	Preservative-free bimatoprost 0.03%/timolol 0.5% fixed combination in patients with glaucoma in clinical practice
title_short	Preservative-free bimatoprost 0.03%/timolol 0.5% fixed combination in patients with glaucoma in clinical practice
title_full	Preservative-free bimatoprost 0.03%/timolol 0.5% fixed combination in patients with glaucoma in clinical practice
title_fullStr	Preservative-free bimatoprost 0.03%/timolol 0.5% fixed combination in patients with glaucoma in clinical practice
title_full_unstemmed	Preservative-free bimatoprost 0.03%/timolol 0.5% fixed combination in patients with glaucoma in clinical practice
title_sort	preservative-free bimatoprost 0.03%/timolol 0.5% fixed combination in patients with glaucoma in clinical practice
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/ecf91b7b927544dbab46409aca22c4e2
work_keys_str_mv	AT pfennigsdorfs preservativefreebimatoprost003timolol05fixedcombinationinpatientswithglaucomainclinicalpractice AT eschstruthp preservativefreebimatoprost003timolol05fixedcombinationinpatientswithglaucomainclinicalpractice AT hasemeyers preservativefreebimatoprost003timolol05fixedcombinationinpatientswithglaucomainclinicalpractice AT feuerhakec preservativefreebimatoprost003timolol05fixedcombinationinpatientswithglaucomainclinicalpractice AT briefg preservativefreebimatoprost003timolol05fixedcombinationinpatientswithglaucomainclinicalpractice AT grobeiui preservativefreebimatoprost003timolol05fixedcombinationinpatientswithglaucomainclinicalpractice AT shirlawa preservativefreebimatoprost003timolol05fixedcombinationinpatientswithglaucomainclinicalpractice
_version_	1718399669094055936

Preservative-free bimatoprost 0.03%/timolol 0.5% fixed combination in patients with glaucoma in clinical practice

Ejemplares similares